Douglas Dulli, MD

The negative results of the Management of Atherothrombosis with Clopidogrel in High-risk patients (MATCH) Trial1 are disappointing and surprising, but perhaps this can be said about the conduct of the trial itself.

One of the great advances in medical practice arose from studies on atrial fibrillation in the 1990s.